Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Breast Neoplasms 7Colorectal Neoplasms 3Lung Neoplasms 2Stomach Neoplasms 1Peripheral Nervous System Diseases 1Pancreatic Neoplasms 1Pain 1Ovarian Neoplasms 1Neoplasms 1Lung Diseases 1Colorectal Neoplasms, Hereditary Nonpolyposis 1Cancer Cachexia 1Cachexia 1Breastcancer 1Biliary Tract Neoplasms 1

Interventions

Carboplatin 10Paclitaxel 5Nivolumab 4Pemetrexed 3Cisplatin 3atezolizumab 2apatinib 2Surveys and Questionnaires 2One-Lung Ventilation 2Ipilimumab 2Blood Specimen Collection 2Bevacizumab 2zimberelimab 1toripalimab 1spartalizumab 1sitravatinib 1sintilimab 1sacituzumab govitecan 1pembrolizumab 1lorlatinib 1cemiplimab 1camrelizumab 1Vital Signs 1Vinorelbine 1Tyrosine Kinase Inhibitors 1Tomography, Emission-Computed, Single-Photon 1Temozolomide 1Telescopes 1Talc 1Saline Solution 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Lung Diseases × Omacor × Clear all
NCT03598309 2026-02-27

Phase II Trial to Modulate Intermediate Endpoint Biomarkers in Former and Current Smokers

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Active not recruiting
19 enrolled
Thoracic

Lung Diseases, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡